Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview.
Chimerix（NASDAQ:CMRX）是一家生物制药公司，其使命是开发能显着改善和延长面临致命疾病患者的生命的药品。今天宣布，将于2024年8月13日星期二上午8:30（东部时间）举行电话会议和网络直播，以报告截至2024年6月30日的第二季度财务业绩和业务概况。
To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on the Investors' section of the Company's website, . An archived webcast will be available on the Chimerix website approximately two hours after the event.
接听直播电话请提前五分钟拨打(646) 307-1963（美国境内）或（800）715-9871（国际长途），并提供会议ID 5436125。调取本次电话会议的网络直播，请在公司网站的投资者版块收听。本次活动结束后大约两个小时，的Chimerix网站将提供已存档的网络直播。
About Chimerix
关于Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
Chimerix是一家生物制药公司，旨在开发有意义地改善和延长面对致命疾病的患者生命的药物。该公司最先进的临床阶段开发项目ONC201正在开发治疗的H3K27M突变性胶质瘤。
CONTACT:
联系人：
Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com
威尔·奥康纳
Stern Investor Relations
212-362-1200
will@sternir.com
Source: Chimerix, Inc.
来源：锤子医药股份有限公司。